Addex Therapeutics Ltd
ADXN8.000USD
-0.380-4.53%
終値 12/24, 13:00（ET）15分遅れの株価
7.77M時価総額
損失額直近12ヶ月PER
詳細情報 Addex Therapeutics Ltd 企業名
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Addex Therapeutics Ltdの企業情報
企業コードADXN
会社名Addex Therapeutics Ltd
上場日May 22, 2007
最高経営責任者「CEO」Dyer (Tim)
従業員数2
証券種類Depository Receipt
決算期末May 22
本社所在地Chemin des Mines, 9
都市PLAN-LES-OUATES
証券取引所NASDAQ OMX - NASDAQ BASIC
国Switzerland
郵便番号1202
電話番号41228841555
ウェブサイトhttps://www.addextherapeutics.com/en/
企業コードADXN
上場日May 22, 2007
最高経営責任者「CEO」Dyer (Tim)
Addex Therapeutics Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Dr. Roger G. Mills
Dr. Roger G. Mills
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sat, Nov 15
更新時刻: Sat, Nov 15
株主統計
種類
株主統計
株主統計
比率
GAMMA Investing LLC
0.01%
他の
99.99%
株主統計
株主統計
比率
GAMMA Investing LLC
0.01%
他の
99.99%
種類
株主統計
比率
Investment Advisor/Hedge Fund
0.01%
他の
99.99%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
11
199.00
18.66%
--
2025Q3
13
199.00
18.82%
-178.00
2025Q2
13
377.00
18.92%
-12.73K
2025Q1
16
13.11K
17.74%
-176.53K
2024Q4
18
15.10K
16.53%
+13.71K
2024Q3
23
37.43K
17.28%
-1.01K
2024Q2
22
38.45K
22.31%
+2.01K
2024Q1
21
36.44K
17.06%
-145.91K
2023Q4
20
195.87K
5.59%
+122.48K
2023Q3
19
73.39K
85.88%
+23.16K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
GAMMA Investing LLC
121.00
0.01%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
72.00
0.01%
--
--
Jun 30, 2025
SBI Securities Co., Ltd.
5.00
0%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
--
0%
-4.00
-100.00%
Dec 31, 2023
Citadel Advisors LLC
--
0%
-11.74K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
100.00
0.01%
--
--
Jun 30, 2025
J. Stern & Co. LLP
--
0%
-107.83K
-100.00%
Mar 31, 2024
Armistice Capital LLC
--
0%
-43.00K
-100.00%
Mar 31, 2024
New Enterprise Associates (NEA)
--
0%
-9.00K
-100.00%
Mar 31, 2024
Adar1 Capital Management LLC
--
0%
-1.00K
-100.00%
Dec 31, 2024
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
日付
種類
比率
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
よくある質問
Addex Therapeutics Ltdの上位5名の株主は誰ですか？
Addex Therapeutics Ltdの上位5名の株主は以下のとおりです。
GAMMA Investing LLCは121.00株を保有しており、これは全体の0.01%に相当します。
Rhumbline Advisers Ltd. Partnershipは72.00株を保有しており、これは全体の0.01%に相当します。
SBI Securities Co., Ltd.は5.00株を保有しており、これは全体の0.00%に相当します。
UBS Financial Services, Inc.は0.00株を保有しており、これは全体の0.00%に相当します。
Citadel Advisors LLCは0.00株を保有しており、これは全体の0.00%に相当します。
GAMMA Investing LLCは121.00株を保有しており、これは全体の0.01%に相当します。
Rhumbline Advisers Ltd. Partnershipは72.00株を保有しており、これは全体の0.01%に相当します。
SBI Securities Co., Ltd.は5.00株を保有しており、これは全体の0.00%に相当します。
UBS Financial Services, Inc.は0.00株を保有しており、これは全体の0.00%に相当します。
Citadel Advisors LLCは0.00株を保有しており、これは全体の0.00%に相当します。
Addex Therapeutics Ltdの株主タイプ上位3種は何ですか？
Addex Therapeutics Ltdの株主タイプ上位3種は、
GAMMA Investing LLC
他の
GAMMA Investing LLC
他の
Addex Therapeutics Ltd（ADXN）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Addex Therapeutics Ltdの株式を保有している機関は11社あり、保有株式の総市場価値は約199.00で、全体の18.66%を占めています。2025Q3と比較して、機関の持ち株は-0.16%増加しています。
Addex Therapeutics Ltdの最大の収益源は何ですか？
--において、--部門がAddex Therapeutics Ltdにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
